Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 82
Switching Peptides: What the Evidence Says
No clinical guideline covers switching between incretin-class peptides. Prescribing information and early research both say: start at the lowest dose.
BPC-157 tested as AChE inhibitor in vitro
A 2026 lab study finds BPC-157 and two hybrid peptides inhibit the enzyme targeted by Alzheimer's drugs, but at low potency and only in vitro.
Which drugs flag for gastric motility risks
A 2026 study screened 58 million adverse-event reports. Semaglutide had the strongest signal for impaired gastric emptying.
Herbs for GLP-1 side effects? A new study
Researchers screened 142,705 FDA adverse event reports to flag five herbal candidates linked to GLP-1 side-effect pathways.
Oral Wegovy tracker: FDA, EMA, MHRA
The FDA, EMA, and MHRA have now all approved oral Wegovy for weight management. Here is the regulatory timeline and how the three decisions compare.
Radiolabeling peptides in fewer steps
A 2026 study reports a hydroformylation method that installs carbon-14 or tritium labels on peptides, including semaglutide analogs.
Stopping semaglutide before abdominoplasty
A retrospective study of 80 patients finds that stopping semaglutide four weeks before abdominoplasty normalised complication rates.
Tb4 with ciprofloxacin restores eye nerves
A 2026 mouse study finds topical thymosin beta-4 with ciprofloxacin restores nerve density and vision after bacterial keratitis.
Peptide Stacks With Tirzepatide
No clinical trial has studied BPC-157, TB-500, or CJC-1295 in combination with tirzepatide. Here is what the evidence shows.
Wegovy weight loss pill gets UK approval
The MHRA approved oral Wegovy (semaglutide 25 mg tablets) for weight management in adults on 11 June 2026, making it the first oral GLP-1 for obesity in the UK.
Optic neuropathy after semaglutide ramp-up
A 2026 case report describes atypical optic nerve damage behind the eye in a man on semaglutide 1 mg weekly, broadening the known spectrum of eye-related risks.
Biopsy-free MASH trials need longer runs
Ajmera and Loomba argue that NIT-based MASH trials must extend beyond 52 weeks and use composite non-invasive endpoints to capture fibrosis change.